Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

Diagnosis: The patient's rheumatic presentation was diagnosed as a paraneoplastic syndrome associated with pancreatic carcinoma. Management: The patient's condition was managed with ...

These results may help guide management strategies and prognostication among patients with advanced NSCLC who experience severe irAE and in whom permanent ICI discontinuation is required,” the ...

She was forced to keep her true identity hidden for years. After Denise developed paraneoplastic syndrome in 2014 – a rare immune response to a tumour – Samantha moved into one of Belong Wigan ...

After Denise developed paraneoplastic syndrome in 2014 – a rare immune response to a tumour – Samantha moved into one of Belong Wigan's independent living apartments to be closer to her wife.

Tragically, in 2014, Denise developed paraneoplastic syndrome – a rare immune response to a tumour in her chest – giving her a six-month life expectancy. After 18 months, she was still alive ...

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the ...

A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition.

The final, formatted version of the article will be published soon. Paraneoplastic syndromes represent a clinically heterogeneous group of disorders that arise in cancer patients. Although their ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.